Exchange: NASDAQ·Updated 07:30 PM EDT
AVTX logo

AVTX Avalo Therapeutics Inc

$14.60
$0.39
(2.60%)
Today
Closed $14.60
$0.00
(0.00%)
After Hours
EarningsNov 12
Mkt Cap$803.91M
Vol736,839.00

About AVTX

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.
53

Neutral Sentiment

How do you feel about AVTX?

OptionRunners
$AVTX the October $10/$30 spreads likely got added to again as well today. Another $3M in those. See if OI confirms tomorrow.
1
2
OptionRunners
$AVTX more of the same spreads from yesterday being added here (potentially). Need to see if the OI confirms on Monday.
1
1
SqueezeSpecs
$AVTX: Avalo Therapeutics will present additional Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa at the EADV 2026 Congress, including a late-breaker oral presentation on October 1. The company plans to advance abdakibart into a registrational Phase 3 program in the first half of 2027. Avalo also reported $472.2M in cash, cash equivalents and investments as of June 30, with management saying its current resources are expected to fund operations into 2029.
2

Advertisement|Remove ads.